Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
42
LYEL Quote, Financials, Valuation and Earnings
Last price:
$25.37
Seasonality move
:
-10.45%
Day range:
$21.39 - $25.59
52-week range:
$7.65 - $25.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
80,900.63x
P/B ratio:
1.00x
Volume:
54.2K
Avg. volume:
35.1K
1-year change:
18.85%
Market cap:
$330.4M
Revenue:
$61K
EPS (TTM):
-$19.59
Analysts' Opinion
-
Consensus RatingLyell Immunopharma, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $19.00, Lyell Immunopharma, Inc. has an estimated downside of -14.84% from its current price of $22.31.
-
Price Target UpsideAccording to analysts, the highest upside price target is $25.00 representing -100% upside increase from its current price of $22.31.
Fair Value
-
According to the consensus of 2 analysts, Lyell Immunopharma, Inc. has -14.84% downside to fair value with a price target of $19.00 per share.
LYEL vs. S&P 500
-
Over the past 5 trading days, Lyell Immunopharma, Inc. has underperformed the S&P 500 by -0.99% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lyell Immunopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lyell Immunopharma, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Lyell Immunopharma, Inc. reported revenues of $15K.
Earnings Growth
-
Lyell Immunopharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Lyell Immunopharma, Inc. reported earnings per share of -$2.13.
Enterprise value:
63.8M
EV / Invested capital:
0.17x
Price / LTM sales:
80,900.63x
EV / EBIT:
--
EV / Revenue:
1,556.53x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$14.1M
Return On Assets:
-69.79%
Net Income Margin (TTM):
-794292.68%
Return On Equity:
-86.7%
Return On Invested Capital:
-75.65%
Operating Margin:
-258960%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $48.5M | $63K | $41K | $34K | $15K | |
| Gross Profit | $29.2M | -$19.6M | -$14.1M | -$4.6M | -$2.6M | |
| Operating Income | -$206.9M | -$220.5M | -$204.1M | -$51.3M | -$38.8M | |
| EBITDA | -$187.6M | -$200.9M | -$190M | -$46.6M | -$36.3M | |
| Diluted EPS | -$0.76 | -$0.80 | -$19.59 | -$0.17 | -$2.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $631.1M | $659.7M | $586.9M | $450M | $328.2M | |
| Total Assets | $1.2B | $977.3M | $795M | $619.2M | $408M | |
| Current Liabilities | $59.3M | $51.2M | $35.1M | $33.5M | $31.9M | |
| Total Liabilities | $211.9M | $157.2M | $97.4M | $88.5M | $78.8M | |
| Total Equity | $986.5M | $820M | $697.6M | $530.7M | $329.1M | |
| Total Debt | $65.7M | $64.6M | $58.6M | $51.4M | $44.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$163.3M | -$155.8M | -$165M | -$35M | -$28.6M | |
| Cash From Investing | $331.4M | -$31.8M | $139M | $1.9M | $3.3M | |
| Cash From Financing | $1.8M | $1.6M | $50.6M | -- | $50M | |
| Free Cash Flow | -$170.6M | -$156.2M | -$165.5M | -$35.1M | -$28.6M | |
LYEL
Sector
Market Cap
$330.4M
$28.4M
Price % of 52-Week High
88.53%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-20.46%
-1.32%
1-Year Price Total Return
18.85%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.25
200-day SMA
Buy
Level
$12.37
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$19.34
Relative Strength Index (RSI14)
Buy
Level
69.72
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-34.2823
50-day SMA
Buy
Level
$17.71
MACD (12, 26)
Buy
Level
1.56
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.4969)
Sell
CA Score
(Annual)
Level (-0.5485)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.949)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, LYEL has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LYEL average analyst price target in the past 3 months is $19.00.
-
Where Will Lyell Immunopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lyell Immunopharma, Inc. share price will drop to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Lyell Immunopharma, Inc.?
Analysts are divided on their view about Lyell Immunopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lyell Immunopharma, Inc. is a Sell and believe this share price will rise from its current level to $12.00.
-
What Is Lyell Immunopharma, Inc.'s Price Target?
The price target for Lyell Immunopharma, Inc. over the next 1-year time period is forecast to be $19.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LYEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lyell Immunopharma, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of LYEL?
You can purchase shares of Lyell Immunopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lyell Immunopharma, Inc. shares.
-
What Is The Lyell Immunopharma, Inc. Share Price Today?
Lyell Immunopharma, Inc. was last trading at $25.37 per share. This represents the most recent stock quote for Lyell Immunopharma, Inc.. Yesterday, Lyell Immunopharma, Inc. closed at $22.31 per share.
-
How To Buy Lyell Immunopharma, Inc. Stock Online?
In order to purchase Lyell Immunopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LYEL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LYEL
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
1.00x
1.84x
Price / LTM sales
80,900.63x
1.60x
Growth Metrics
LYEL
Sector
Revenue growth
-55.88%
4.85%
Earnings growth
-1122.77%
11.15%
Revenue (5-year growth)
-37.83%
6.45%
Earnings forecast
-$2.30
-$0.20
Profitability
LYEL
Sector
Profitability FY 2024
-$19.6M
$3.6M
Return on invested capital
-75.65%
-30.98%
Return on assets
-69.79%
-27.62%
Return on equity
-86.7%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
11
Balance Sheet
LYEL
Sector
Total cash
$319.6M
$27.2M
Short term investments
$264.9M
$25.7M
Total assets
$490.9M
$79.9M
Long term debt
$44.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
